TickerFacts.

Compare

Vir Biotechnology, Inc. vs Recursion Pharmaceuticals, Inc. vs Autolus Therapeutics plc vs Champions Oncology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearVir Biotechnology, Inc.
VIR		Recursion Pharmaceuticals, Inc.
RXRX		Autolus Therapeutics plc
AUTL		Champions Oncology, Inc.
CSBR
Year ended2025-12-312025-12-312025-12-312026-04-30
Revenue$68.56M$74.68M$75.39M$59.42M
Revenue growth (YoY)-7.6%+26.9%+644.9%+4.4%
Gross marginn/a5.0% (computed)-27.8% (computed)48.0% (computed)
Operating margin-699.2%-867.9%-358.9%-1.9%
Net margin-638.9%-863.4%-381.4%-2.0%
Net income-$437.99M-$644.76M-$287.53M-$1.18M
EPS (Diluted)-$3.16-$1.44-$1.08-$0.08
Operating cash flow-$391.78M-$371.81M-$283.57M-$4.47M
Free cash flow-$396.61M-$378.28M-$302.61M-$5.04M
Cash & equivalents$232.19M$743.29M$104.13Mn/a
Total assets$1.00B$1.47B$589.07M$26.99M
Total liabilities$237.55M$343.26M$410.94M$22.92M
Shareholders' equity$765.28M$1.13B$178.13M$3.94M
Return on year-end equity-57.2%-57.0%-161.4%-29.8%
Shares outstanding139.47M528.18Mn/a13.89M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearVir Biotechnology, Inc.Recursion Pharmaceuticals, Inc.Autolus Therapeutics plcChampions Oncology, Inc.
Latest$68.56M
Ended 2025-12-31		$74.68M
Ended 2025-12-31		$75.39M
Ended 2025-12-31		$59.42M
Ended 2026-04-30
1 year earlier$74.20M
Ended 2024-12-31		$58.84M
Ended 2024-12-31		$10.12M
Ended 2024-12-31		$56.94M
Ended 2025-04-30
2 years earlier$86.18M
Ended 2023-12-31		$44.58M
Ended 2023-12-31		$1.70M
Ended 2023-12-31		$50.16M
Ended 2024-04-30
3 years earlier$1.62B
Ended 2022-12-31		$39.84M
Ended 2022-12-31		n/a$53.87M
Ended 2023-04-30
4 years earlier$1.10B
Ended 2021-12-31		$10.18M
Ended 2021-12-31		n/a$49.11M
Ended 2022-04-30